Agile therapeutics inc (AGRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-7,883

-6,021

-4,432

-3,484

-4,669

-3,810

-3,792

-5,344

-6,833

-6,240

-7,103

-7,445

-7,516

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,318

-

-9,411

-8,487

-8,538

-

-

-

-

Net loss (income)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

839

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

4

4

4

5

5

5

6

6

6

7

5

6

5

5

5

5

4

4

4

5

5

4

2

2

2

Amortization

40

38

36

33

38

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash stock bonus

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

80

Noncash stock bonus

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

80

Noncash stock based compensation

621

415

378

479

490

803

721

987

1,119

924

967

925

835

818

941

955

711

836

746

738

645

407

381

364

228

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-1,036

-

-

-

-

Noncash interest

-

-

-

-

-

-85

105

123

139

147

160

174

186

187

415

172

172

173

172

172

73

46

47

58

33

Noncash interest

101

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

0

0

-22

-7

-61

20

7

-109

-66

-38

63

-193

155

-105

-41

101

-69

-86

-179

-12

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-168

-476

1,138

-200

-229

-124

531

-433

-129

-400

637

-2,000

-243

-327

1,022

-961

-656

-

-

-

-

-565

2,385

565

-51

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

443

395

-308

-

-

-

-

Accounts payable and accrued expenses

-891

1,858

109

425

-1,015

-173

-360

-375

-269

-987

-243

-1,578

348

1,010

120

3

-771

-1,658

1,820

461

724

378

616

1,894

-290

Lease liability

44

40

37

36

39

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-7,884

-3,270

-5,080

-2,378

-4,961

-3,136

-3,851

-4,192

-5,716

-5,810

-6,831

-5,911

-6,008

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,739

-

-7,217

-7,547

-5,646

-5,511

-7,778

-2,144

931

Acquisition of property and equipment

164

-

-

-

-

0

2

40

276

542

321

445

5

6

5

18

2

2

13

86

189

53

35

5

1

Net cash used in investing activities

-164

-

-

-

-

0

-2

-40

-276

-542

-321

-445

-5

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from issuance of common stock in private placement, net of offering costs

-

-

0

0

7,810

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sales or issuance of common stock, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

-20

37,547

-

0

0

19,330

-

-

-

-

Proceeds from issuance of long-term debt

20,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

-

-13

-86

-189

-53

-35

-5

-1

Cash paid for offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

40

Proceeds from issuance term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

16,265

-

-

-

-

Repayment of term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

15,784

-

-

-

-

Principal payments of long-term debt

-

-

-

-

-

5,939

1,686

1,647

1,616

1,577

1,539

1,503

993

-

-

-

-

-

-

-

-

-

-

-

-

Debt financing costs paid

1,059

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

423

-

-

-

-

Proceeds from exercise of stock options

119

-

-

-

-

-

-

-

-

-

-

-

-

5

9

26

294

61

227

175

130

-

-

-

-

Net cash provided by financing activities

67,494

19,447

12,894

1,404

8,670

-5,939

-1,686

-1,647

-1,616

-1,502

17,020

-1,450

-993

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

59,446

16,109

7,784

-974

3,709

-9,075

-5,539

-5,879

-7,608

-7,854

9,868

-7,806

-7,006

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

375

-

379

380

339

345

345

345

345

Supplemental disclosure of noncash financing activities
Warrants issued in connection with long-term debt

3,570

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

37,841

-

227

175

19,518

67

0

52,633

-40

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

31,100

-

-7,003

-7,458

13,683

-5,498

-7,814

50,484

890

Supplemental cash flow information
Interest paid

297

-

-

-

-

745

176

210

239

272

310

345

368

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of common stock warrants issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,184

-

-

-

-

At-the-market sales
Proceeds from sales or issuance of common stock, net of offering costs

-

-

-

-

860

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public offering
Proceeds from sales or issuance of common stock, net of offering costs

48,434

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-